GlaxoSmithKline and Johnson & Johnson will become pharma partnering for increasing production of an Ebola vaccine, with an aim to produce at least 1 million doses next year.
So far, there is no proven vaccine for Ebola, but many pharmaceutical companies have been working on experimental drugs that show promise.
J&J has said that it will produce 250,000 doses by May.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity